177 related articles for article (PubMed ID: 7620219)
1. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
Overgaard J
Oncol Res; 1994; 6(10-11):509-18. PubMed ID: 7620219
[TBL] [Abstract][Full Text] [Related]
2. Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers.
Overgaard J; Horsman MR
Semin Radiat Oncol; 1996 Jan; 6(1):10-21. PubMed ID: 10717158
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
4. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
5. Update: the potential for chemosensitization of alkylating agents by nitroimidazoles.
Mulcahy RT
Oncology (Williston Park); 1988 Dec; 2(12):17-24, 27, 30-1 passim. PubMed ID: 3079289
[TBL] [Abstract][Full Text] [Related]
6. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
7. [Clinical trials of hypoxic cell sensitizer misonidazole].
Onoyama Y
Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies of hypoxia modification in radiotherapy.
Kaanders JH; Bussink J; van der Kogel AJ
Semin Radiat Oncol; 2004 Jul; 14(3):233-40. PubMed ID: 15254866
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia in head and neck cancer: how much, how important?
Janssen HL; Haustermans KM; Balm AJ; Begg AC
Head Neck; 2005 Jul; 27(7):622-38. PubMed ID: 15952198
[TBL] [Abstract][Full Text] [Related]
10. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies.
Magagnin MG; Koritzinsky M; Wouters BG
Drug Resist Updat; 2006; 9(4-5):185-97. PubMed ID: 16926105
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
14. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
Hodgkiss RJ
Anticancer Drug Des; 1998 Sep; 13(6):687-702. PubMed ID: 9755725
[TBL] [Abstract][Full Text] [Related]
15. [Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer].
Murayama C; Mori T
Gan No Rinsho; 1990 Oct; 36(13):2249-54. PubMed ID: 2147449
[TBL] [Abstract][Full Text] [Related]
16. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
17. In vitro testing of chemosensitivity in physiological hypoxia.
Grigoryan R; Keshelava N; Anderson C; Reynolds CP
Methods Mol Med; 2005; 110():87-100. PubMed ID: 15901930
[TBL] [Abstract][Full Text] [Related]
18. Misonidazole in the clinic at Mount Vernon.
Dische S
Cancer Clin Trials; 1980; 3(2):175-8. PubMed ID: 7000388
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
20. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
